ArticleCancer medicine2023

Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients.

Jianming Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.